Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cambrex Corporation (NYSE:CBM) Share Price
Media stories about Cambrex Corporation (NYSE:CBM) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex Corporation earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 48.101414141858 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Cambrex Corporation (CBM) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
- Buckingham Asset Management LLC Has $733000 Stake in QUALCOMM Incorporated (QCOM) (wisdomsave.com)
- IHS Markit Score downgrades Cambrex Corp to 21 out of 100, ranking positively in only one out of three available IHS Markit categories. (finance.yahoo.com)
- Cambrex Corporation (NYSE:CBM) Closed -7.3% Below Its 50 Day Moving Average (highlightpress.com)
- See what the IHS Markit Score report has to say about Cambrex Corp. (finance.yahoo.com)
Several equities analysts recently weighed in on CBM shares. Zacks Investment Research upgraded Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research note on Thursday, May 11th. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Cambrex Corporation presently has an average rating of “Buy” and a consensus price target of $64.00.
Cambrex Corporation (NYSE CBM) traded down 0.85% during midday trading on Friday, reaching $52.80. The company’s stock had a trading volume of 191,728 shares. The firm has a market capitalization of $1.73 billion, a P/E ratio of 19.23 and a beta of 2.28. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The company’s 50-day moving average is $58.46 and its 200 day moving average is $55.48.
Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same period last year, the firm earned $0.68 EPS. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. Analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.
In other news, VP Samantha Hanley sold 14,000 shares of Cambrex Corporation stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $57.56, for a total transaction of $805,840.00. Following the completion of the sale, the vice president now directly owns 1,500 shares in the company, valued at approximately $86,340. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $5,165,824.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,656 shares of company stock valued at $4,064,423. Insiders own 2.48% of the company’s stock.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.